Chromocell Therapeutics 5/15/2024 Earnings Report

Chromocell Therapeutics EPS Results

• Actual EPS: -$5.50
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Chromocell Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Chromocell Therapeutics Announcement Details

• Date: 5/15/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Chromocell Therapeutics (NYSE:CHRO) is a clinical-stage biotechnology company focused on the development of autologous cell therapies for the treatment of peripheral nerve injury and degenerative neuropathies. Headquartered in Greater Boston, the company leverages proprietary technologies to isolate, expand and reinfuse patient-derived supportive cells, aiming to repair damaged nerves and restore function. Chromocell’s mission centers on addressing conditions for which there are currently limited or no effective therapeutic options, including chronic compressive lesions and diabetic neuropathy.

At the core of Chromocell’s pipeline is the OmniChrom™ cell manufacturing platform, designed to produce highly purified Schwann cell products with consistent potency and safety profiles. The lead clinical candidate, CHRO-101, is an autologous Schwann cell therapy being evaluated in Phase 1/2 trials for patients suffering from carpal tunnel syndrome and other compressive neuropathies. In parallel, preclinical programs seek to extend the platform’s potential to sensory and motor nerve injuries, leveraging transitional state Schwann cells to enhance nerve regeneration in both peripheral and, eventually, central nervous system indications.

Founded in 2018 as a spin-out from leading academic research institutions, Chromocell has since built a multidisciplinary team of experts in cell biology, neurology and scalable manufacturing. The company’s operations span the United States and Europe, working collaboratively with clinical sites and regulatory agencies to advance its cell therapy candidates. Under the guidance of a management team with decades of experience in biotech development and clinical translation, Chromocell Therapeutics aims to establish a new standard for regenerative medicine in neurodegenerative and nerve injury disorders.